Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Solti Group
Sponsor

Solti Group

Spain Gran Via De Carles III 86 Planta 9, 08028 Barcelona, Spain

About the sponsor

Research activity is centered on advanced and metastatic HER2-positive breast cancer, including disease that has progressed after prior trastuzumab-based treatment. The sponsor also funds studies in locally advanced settings and in patients receiving HER2-targeted therapy combined with other systemic approaches.

  • Trastuzumab deruxtecan
  • Pertuzumab
  • HER3-directed therapy
  • Anti-HER2 ADCs

These trials include biomarker-linked work in ERBB2 expression and treatment-sensitive subgroups within HER2-positive disease.

About Specializations

Solti Group runs clinical trials in conditions such as Hormone receptor positive HER2 negative breast cancer, HER2 positive breast cancer, Metastatic neoplasm, Hormone receptor positive breast cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Hormone receptor positive breast cancer

Recruiting

Study on Elacestrant and Triptorelin for Premenopausal Women with Early Luminal Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tamoxifen Citrate
  • Sponsor:Solti Group

Phase Ib/II Study of Zongertinib Combined with Ribociclib and Trastuzumab in Patients with Metastatic ER‑positive/HER2‑positive Breast Cancer

Not yet recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ribociclib
  • Sponsor:Solti Group

HER2 positive breast cancer

Not recruiting

Study of Atezolizumab, Trastuzumab, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Solti Group

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Solti Group

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:Solti Group

HER2 negative breast cancer

Not recruiting

Study on Olaparib for Patients with Advanced HER2-Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Solti Group

HER2 positive breast cancer

Not recruiting

Study of Ipatasertib with Trastuzumab and Pertuzumab for Patients with Advanced HER2-Positive Breast Cancer and PIK3CA Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipatasertib
  • Sponsor:Solti Group

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Solti Group

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solti Group

Metastatic neoplasm

Not recruiting

Study on the Effects of Trastuzumab Deruxtecan in Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Solti Group

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Solti Group

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.